Another Uplisting .com Client Successfully Uplists to Nasdaq Capital Markets
On November 2, 2018, Uplisting.com client, Avalon Globocare Corp (“Avalon Globocare” or the “Company”), finalized its uplisting to the NASDAQ Capital Markets. Its common stock began trading on the exchange on November 5, 2018, under the symbol AVCO.
Avalon Globocare is dedicated to integrating and managing global healthcare services and resources, as well as empowering high-impact biomedical innovations and technologies to accelerate their clinical applications. Operating through two major platforms, namely “Avalon Cell” and “Avalon Rehab”, their “Technology + Service” ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company plans to integrate these services through joint ventures that bring shareholder value both in the short term, through operational entities as part of Avalon Rehab, and long term, through biomedical innovation development as part of Avalon Cell, such as their recent joint venture for the advancement of exosome isolation systems and related products.
Avalon Globocare currently generates revenue by selling exosome isolation systems in China and the United States through their joint venture, GenExosome Technologies, Inc. In addition, they provide medical-related consulting services in advanced areas of immunotherapy and second opinion/referral services through their wholly-owned subsidiary, Avalon (Shanghai) Healthcare Technology Co., Ltd., or Avalon Shanghai. The Company also owns and operates commercial real estate in New Jersey, where they are headquartered.
Avalon Globocare provides an example of an OTC company that was able to uplist to a higher exchange. Uplisting.com worked hand-in-hand with the management of Avalon Globocare and its professionals in the process of uplisting to NASDAQ and believes this company can inspire other companies to move forward with the uplisting process.
Todd Heinzl, Managing Director of Uplisting.com said, “We are confident that Avalon Globocare will be a valued addition to NASDAQ Capital Markets and Uplisting.com is pleased that we were able to assist with this uplist process. We wish them success as a NASDAQ Capital Markets issuer.”
Mr. Heinzl is also a regular PubCoCEO.com contributor and author of our Uplisting Series in which he describes the process and benefits of Uplisting from the OTC Markets to a Senior Exchange. You can view each part of the Uplisting Series via the links below.